List view / Grid view
Biomedical Advanced Research and Development Authority (BARDA)
The first participants ages 12 to less than 18 have been dosed in the study of mRNA-1273, Moderna's vaccine candidate against COVID-19.
The company announces it has been task ordered by BARDA to assist in the US government’s efforts to deliver COVID-19 vaccines.
The US FDA has given Fast Track Designation to Moderna's mRNA vaccine candidate, mRNA-1273, designed to protect against COVID-19.
The US Biomedical Advanced Research and Development Authority (BARDA) will fund Moderna’s COVID-19 vaccine candidate mRNA-1273 through Phase II and III clinical trials to FDA licensure.
Sanofi will provide its S protein antigen and GSK will contribute its adjuvant technology in a partnership to develop a COVID-19 vaccine.
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
Following the selection of a COVID-19 vaccine lead, Johnson & Johnson (J&J) aims to begin clinical trials in humans later this year while also scaling up its manufacturing facilities.
27 September 2016 | By Niamh Louise Marriott, Digital Content Producer
In July, Sanofi revealed the development agreement with the Walter Reed Army Institute of Research on the co-development of a Zika vaccine candidate...
7 July 2015 | By Victoria White
BARDA, a division of the US Department of Health & Human Services, has ordered a bulk supply of Bavarian Nordic’s Imvamune non-replicating smallpox vaccine...
19 September 2013 | By GSK
The US government is purchasing the medicine as a counter measure against a potential bioterrorist attack...